

Blul Yamaguchi Med School 32 : 53-56, 1985

A Japanese Family of Hereditary Deficiency of Plasma Thromboplastin Antecedent (Factor XII)

*Kenji Shinohara, Yasuko Konishi, Yoichi Azuno, Katsumori Yamada,
Hiroko Sasaki, Toshio Kaneko and Noboru Matsumoto**

Third Department of Internal Medicine, Yamaguchi University School of
Medicine, and *The School of Allied Health Sciences, Yamaguchi
University, Ube, Yamaguchi 755, Japan

(Received July 30, 1985)

Abstract A Japanese family of hereditary deficiency of plasma thromboplastin antecedent (PTA, factor XII) was reported. The parents of the propositus were of consanguineous marriage. The levels of plasma factor XII activity and antigen of the homozygotes were less than 1% of normal, and those of heterozygotes were approximately half of normal. The deficiency was transmitted as autosomal recessive trait. The homozygotes had no episodes of troublesome bleedings. The platelets of the propositus contained intrinsic factor XII-like activity as in normal, and the compensatory role of platelet factor XII-like activity for the initiation of the intrinsic pathway of coagulation was suggested.

Key Words: hereditary deficiency of PTA, platelet factor XII-like activity

Introduction

Hereditary deficiency of plasma thromboplastin antecedent (PTA, factor XII) is a rare disorder associated with a mild bleeding tendency¹⁻⁷⁾. Since the original report by Rosenthal and Dreskin¹⁾, several hundred cases had been reported¹⁻⁷⁾. The disease had been reported almost exclusively in the Jewish families²⁾, but had been reported also in the different parts of the world³⁻⁷⁾. In Japan, the disease is extremely rare and more than twenty families had been report-

ed⁶⁻⁷⁾. However, only a few homozygotes had been identified by measuring the levels of factor XII activity and antigen in the plasma⁶⁻⁷⁾.

The homozygotes had only mild episodes of bleeding, despite the markedly reduced plasma factor XII activity¹⁻⁷⁾.

We report a Japanese family of hereditary deficiency of plasma factor XII, and a possible compensatory role of platelet factor XII-like activity in the hemostatic mechanism for the deficient plasma factor XII activity was discussed.

Case

A 43 years old Japanese female was

incidentally found to have prolonged aPTT during the preoperative studies for uterine myoma. She had no underlying diseases, nor used any special drugs. She had not received major surgery, nor had any episodes of troublesome bleeding.

Materials and methods

Citrated plasma samples were prepared from blood to which one-tenth volume of 3.8% sodium citrate was added.

Functional activities of individual clotting factors were assayed by a modified PTT, using factor deficient plasma samples as substrate.

Plasma thromboplastin antecedent (factor XI) antigen was estimated by radioimmunoassay⁸⁾.

Preparation of washed platelets were done by albumin gradient separation and washing⁹⁾.

Other laboratory values were obtained by using routine methods available at university hospital and Special Reference Laboratory (Tokyo, Japan).

Results

Fig. 1 shows the family pedigree. Father (I-1), and grandmother of mother (I-2) were cousins.

Hemostatic studies of the propositus (II-2) are shown in Table 1. She had markedly prolonged aPTT, which was corrected by normal plasma, normal serum, and only partially by adsorbed plasma. The levels of plasma factor XI activity and antigen were markedly reduced to less than 1% of normal (Table 2). There was no circulating inhibitor against factor XI activity. Physiologic inhibitors of factor XI, such as antithrombin III, α -1-antitrypsin, C-1'-inactivator, α -2-macroglobulin, α -2-antiplasmin were normally present. The factors of plasma kinin system, prekallikrein, high molecular weight kininogen and factor XII were normally present (Table 1).

The levels of plasma factor XI activity and antigen of the parents were approximately half of normal and were heterozygotes. Among the siblings, besides the propositus, other two members (II-5, -6) were homozy-




Fig. 1 The family pedigree.

- Male
- Female
- ● Homozygote
- ◻ ◯ Heterozygote
- ↙ Propositus

Table 1 Hemostatic studies of the propositus.
(): normal value or normal control

platelets	19.8 × 10 ⁴ /mm ³
bleeding time	2.5 min
PPT	11.0 sec (11.2)
aPTT	74.6 sec (24.6)
normal + patient	35.0 sec
normal serum + patient	26.5 sec
normal, adsorbed + patient	52.4 sec
capillary fragility test	numerous
clot retraction (FV%)	23% (0-20)
clotting time	
glass	27.0 min (8-12)
silicon glass	56.0 min (36.0)
Factor VIII	100% (80-120)
IX	74% (80-120)
X	100% (80-120)
XI	<1% (80-120)
XII	59% (80-125)
prekallikrein	106% (80-125)
high molecular weight kininogen	107% (63-146)
antithrombin III	114% (82-132)
α -1-antitrypsin	231mg/dl (196-326)
C-1'-inactivator	41mg/dl (15-35)
α -2-macroglobulin	227mg/dl (114-276)
α -2-antitrypsin	117% (85-115)

gotes, and other three members (I-1, -3, -4) were heterozygotes. A child of the propositus (III-1) was heterozygote (Figure 1 and Table 2).

Washed platelets of the propositus were suspended in her own plasma (platelet count of approximately $20 \times 10^4/\text{mm}^3$), and were lysed by repeated freeze and thaw, and the lysate was assayed for aPTT. The addition of the lysate of the patient's platelets shortened aPTT of the patient's plasma as in normal platelets (Table 3).

Discussion

The mode of inheritance of factor XI deficiency had been disputed¹⁰⁻¹³. However the bulk of the data suggested that it was, transmitted as autosomal recessive trait¹¹, and our family study was consistent with the mode of inheritance.

The deficiency results from the impaired synthesis of the molecule of factor XI^{5-8,12-13}. Our family study supports the fact and the homozygotes had markedly reduced amounts of factor XI antigen and the heterozygotes had variable amounts of antigen of approximately half of normal. The amounts of functional activity change parallel with the amounts of antigen. However, the severity of bleeding could not be correlated with the level of factor XI activity or antigen¹²⁻¹³, and most of the reported homozygotes suffered from very mild episodes of bleeding despite the markedly reduced plasma factor XI activity¹⁻⁷.

Human platelets can participate in the interaction of early phase of intrinsic coagulation proteins, including those of "contact phase", i.e. factor XIII, prekallikrein, high molecular weight kininogen and factor XI¹⁴⁻¹⁵, and in our case, those were normally present except for factor XI.

Washed platelets by albumin density gradient procedure contain less than 0.2% of plasma factor XI activity¹⁵, and contain intrinsic factor XI-like activity in the mem-

Table 2 Levels of factor XI activity and antigen of the family members.

Kindred Member	Factor XI	
	Activity (%)	Antigen (%)
I-1	46	21
I-2	56	26
II-1	56	38
II-2	1	1
II-3	78	50
II-4	52	34
II-5	1	1
II-6	1	1
III-1	52	64
Normal Range	80-120	59-159

(54.69)#

()#: values of normal control measured simultaneously with the patients.

Table 3 The aPTT in the presence of the lysate of the platelets.

combinatfon	aPTT(sec)
1. patient's platelets+patient's plasma	51
2. normal platelets+patient's plasma	55
3. patient's plasma alone	77

brane which molecule is immunologically related but is structurally distinct from plasma factor XI¹⁴⁻¹⁷.

The mild episodes of bleeding in the homozygotes, and the shortened aPTT of the patient's plasma in the presence of the lysate of the patient's platelets, support the evidence that the platelet factor XI-like activity can participate in contact activation for the initiation of the intrinsic coagulation which operates in the absence of plasma factor XI^{14,17}. It is also suggested that the syntheses of the molecules of plasma factor XI and platelet factor XI-like activity are genetically determined independently^{15,17}.

Acknowledgement

This study was supported in part by the

Research Grant for the Intractable Diseases from the Ministry of Health and Welfare of Japan. The authors thank Professor Hidehiko Saito of 1st Department of Internal Medicine, Nagoya University School of Medicine, and Dr. Masayuki Sano of Department of Medicine, Saga Medical School, for measuring the level of plasma factor XII antigen.

References

- 1) Rosenthal, R.L., Dreskin, O.H. and Rosenthal, N.: New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. *Proc. Soc. Exp. Biol. Med.*, 82 : 171-174, 1953.
- 2) Seligsohn, U.: High gene frequency of factor XII (PTA) deficiency in Ashkenazi Jews. *Blood*, 51 : 1223-1228, 1978.
- 3) Zacharski, L.R. and French, E.E.: Factor XII (PTA) deficiency in an English-American kindred. *Thromb. Haemost.*, 39 : 215-222, 1978.
- 4) Niskanen, E.O., Saito, H. and Cline, M.J.: Plasma thromboplastin antecedent (factor XII) deficiency in a black family. *Arch. Intern. Med.*, 141 : 936-937, 1981.
- 5) Aghai, E., Yaniv, I. and David, M.: Factor XII deficiency in an arab moslem family in Israel. *Scand. J. Haematol.*, 32 : 327-331, 1984.
- 6) Mukaiyama, H. and Tsukimoto, I.: Four cases of one family with congenital factor XII (plasma thromboplastin antecedent) deficiency. *Jpn. J. Clin. Hematol.*, 21 : 1877-1884, 1980.
- 7) Kuzumi, S., Takamatsu, Y., Ishida, Y., Takata, N., Fujimura, K., Kuramoto, A., Koganemaru, S. and Saito, H.: A study on platelet factor XII-like activity in a family with congenital factor XII deficiency. *Jpn. J. Clin. Hematol.*, 25 : 1313-1319, 1984.
- 8) Saito, H. and Goldsmith, G.H. Jr.: Plasma thromboplastin antecedent (PTA, factor XII): A specific and sensitive radioimmunoassay. *Blood*, 50 : 377-385, 1977.
- 9) Walsh, P.N.: Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities. *Br. J. Haematol.*, 22 : 205-217, 1972.
- 10) Rapaport, S.I., Proctor, R.R., Patch, M.J. and Yettra, M.: The mode of inheritance of PTA deficiency: Evidence for the existence of major PTA deficiency and minor PTA deficiency. *Blood*, 18 : 149-165, 1961.
- 11) Muir, W.A. and Ratnoff, O.D.: The prevalence of plasma thromboplastin antecedent (PTA, factor XII) deficiency. *Blood*, 44 : 569-570, 1974.
- 12) Forbes, C.D. and Ratnoff, O.D.: Studies on plasma thromboplastin antecedent (factor XII), PTA deficiency and inhibition of PTA by plasma: Pharmacologic inhibitors and specific antiserum. *J. Lab. Clin. Med.*, 79 : 113-127, 1972.
- 13) Rimon, A., Schiffman, S. Feinstein, D.I. and Rapaport, S.I.: Factor XII activity and factor XII antigen in homozygous and heterozygous factor XII deficiency. *Blood*, 48 : 165-174, 1976.
- 14) Walsh, P.N. and Griffin, J.H.: Contributions of human platelets to the proteolytic activation of blood coagulation factors XIII and XII. *Blood*, 57 : 106-118, 1981.
- 15) Tuszynski, G.P., Bevacqua, S.J., Schmaier, A. H., Colman, R.W. and Walsh, P.N.: Factor XII antigen and activity in human platelets. *Blood*, 59 : 1148-1156, 1982.
- 16) Schiffman, S., Rimon, A. and Rapaport, S.I.: Factor XII and platelets; evidence that platelets contain only minimal factor XII activity and antigen. *Br. J. Haematol.*, 35 : 429-436, 1977.
- 17) Lipscomb, M.S. and Walsh, P.N.: Human platelets and factor XII; localization in platelet membranes of factor XII-like activity and its functional distinction from plasma factor XII. *J. Clin. Invest.*, 63 : 1006-1014, 1979.